China Semaglutide Market Size & Outlook, 2024-2035
Related Markets
China semaglutide market highlights
- The China semaglutide market generated a revenue of USD 911.1 million in 2024 and is expected to reach USD 4,225.1 million by 2035.
- The China market is expected to grow at a CAGR of 14.1% from 2025 to 2035.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2024.
- Rybelsus (oral semaglutide) is the most lucrative product segment registering the fastest growth during the forecast period.
Semaglutide market data book summary
| Market revenue in 2024 | USD 911.1 million |
| Market revenue in 2035 | USD 4,225.1 million |
| Growth rate | 14.1% (CAGR from 2025 to 2035) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Rybelsus (oral semaglutide) |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2035 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (oral semaglutide) |
Other key industry trends
- In terms of revenue, China accounted for 3.2% of the global semaglutide market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2035.
- In Asia Pacific, China semaglutide market is projected to lead the regional market in terms of revenue in 2035.
- Japan is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,890.7 million by 2035.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Semaglutide Market Scope
Semaglutide Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China semaglutide market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to semaglutide market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 104.21% in 2024. Horizon Databook has segmented the China semaglutide market based on ozempic (semaglutide), wegovy (semaglutide), rybelsus (oral semaglutide) covering the revenue growth of each sub-segment from 2018 to 2035.
China’s market is growing rapidly, supported by government policies promoting healthcare modernization and local biopharma expansion.
Increasing demand for diabetes and obesity treatments, coupled with the rise of online pharmacies, is transforming market accessibility. The country is seeing significant investments in GLP-1 receptor agonist research and manufacturing.
Reasons to subscribe to China semaglutide market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China semaglutide market databook
-
Our clientele includes a mix of semaglutide market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China semaglutide market , including forecasts for subscribers. This country databook contains high-level insights into China semaglutide market from 2018 to 2035, including revenue numbers, major trends, and company profiles.
Partial client list
China Product - Semaglutide Market size, 2024 - 2035 (US$M)
China Semaglutide Market Outlook Share, 2024 & 2035 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
